Tissue Regenix Group PLC (FRA:LSW)

Half Year 2025 Tissue Regenix Group PLC Earnings Call Transcript

Sep 30, 2025 / 03:00 PM GMT

Release Date Price: €0.199 (-5.24%)

Transcript

Key Points

Positve

Tissue Regenix Group PLC (STU:LSW) reported a 4% increase in orders for demineralized bone matrix products, indicating growth in this segment.
The Dal business grew by 10% year over year in the first half of 2025, despite challenges with a strategic partner.
The company received an EU patent on its D cell process, strengthening its intellectual property position.
Tissue Regenix achieved MDR certification, a significant regulatory milestone for its Orthopure XT business.
The company maintains a high cash collection rate of 98%, demonstrating effective cash management.

Negative

Overall group revenues declined by 6% in the first half of 2025 compared to the same period in 2024.
The Byron's business experienced a 7% decline, impacting overall financial performance.
Gross profit decreased due to increased inventory costs and decreased production yields.
The company faced significant delays in obtaining Certificates to Foreign Governments (CFGs), affecting its ability to export products.
A 45% year-on-year decrease was noted in the RDD business due to regulatory approval delays.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

TRX.L - Tissue Regenix Group PLC
Half Year 2025 Tissue Regenix Group PLC Earnings Call
Sep 30, 2025 / 03:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon and welcome to the Tishi Gen X Group PLC Inim Results Investors presentation. Throughout this recorded presentation, investors will be in listen-only mode. Questions are encouraged and they can be submitted at any time using the Q&A tabs situated on the right hand corner of your screen. Simply type in your questions and press send. The company may not be in a position to answer every question received during the meeting itself. However, the company can review questions submitted today and published responses. What is appropriate to do so. Before we begin, I would like to submit the following poll, and I would now like to hand you over to the management team of Tishioogenics Group. J, good afternoon to

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.